Renal Cancer - Results from #160

Choi response criteria for prediction of survival in patients with metastatic renal cell carcinoma treated with anti-angiogenic therapies, "Beyond the Abstract," by PD Dr. med. Silke Potthast April 26, 2013

Renal functional and perioperative outcomes of off-clamp versus clamped robot-assisted partial nephrectomy: Matched cohort study, "Beyond the Abstract," by Sherb Figenshau, MD April 25, 2013

A concise review of the efficacy of stereotactic radiosurgery in the management of melanoma and renal cell carcinoma brain metastases, "Beyond the Abstract," by Christopher M. Lee, MD April 22, 2013

Off-clamp robot-assisted partial nephrectomy for complex renal tumors, "Beyond the Abstract," by Eric H. Kim, MD, et al March 19, 2013

A validated tumorgraft model reveals activity of dovitinib against renal cell carcinoma, "Beyond the Abstract," by James Brugarolas, MD, PhD March 18, 2013

What is the optimal therapy for patients with metastatic renal cell carcinoma who progress on an initial VEGFr-TKI? "Beyond the Abstract," by Emiliano Calvo, MD, PhD March 11, 2013

Treating patients with metastatic renal carcinoma: An escape from Phase III, "Beyond the Abstract," by Fable Zustovich, MD, et al March 8, 2013

Predicting the histology of small renal masses using preoperative dynamic contrast-enhanced magnetic resonance imaging, "Beyond the Abstract," by Jae Young Park, MD March 2, 2013

Immunotherapy and targeted therapies in metastatic renal cell carcinoma: Is there a preferred sequence? "Beyond the Abstract," by Jacopo Giuliani, MD February 11, 2013

Prognostic factors in renal cell carcinoma: Analysis of 227 patients treated at the Brazilian National Cancer Institute, "Beyond the Abstract," by Antonio Augusto Ornellas, MD, PhD January 31, 2013

A phase II trial of intrapatient dose-escalated sorafenib in patients with metastatic renal cell carcinoma, "Beyond the Abstract," by Robert J. Amato, DO January 25, 2013

Systematic classification and prediction of complications after nephrectomy in patients with metastatic renal cell carcinoma (RCC), "Beyond the Abstract," by Jonathan L Silberstein, MD and Paul Russo, MD, FACS January 25, 2013

VHL-regulated MiR-204 suppresses tumor growth through inhibition of LC3B-mediated autophagy in renal clear cell carcinoma, "Beyond the Abstract," by Nicholas G. Cost, MD and Maria F. Czyzyk-Krzeska, MD, PhD January 21, 2013

Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus, "Beyond the Abstract," by Philippe E. Spiess, MD, MSc, FACS, FRCS(C) January 9, 2013

Renal angiomyoadenomatous tumor: A case report and a brief review of the literature, "Beyond the Abstract," by Charanjeet Singh, MD, J. Carlos Manivel, MD, and Stefan E. Pambuccian, MD December 21, 2012

Can the Kattan nomogram still accurately predict prognosis in renal cell carcinoma using the revised 2010 tumor-nodes-metastasis reclassification? "Beyond the Abstract," by Rajan Veeratterapillay, SpR (Urol) and Rakesh Heer, PhD, F.R.C.S. (Urol) December 10, 2012

CXCR7: A novel tumor endothelial marker in renal cell carcinoma, "Beyond the Abstract," by Kyoko Hida, DDSc, PhD, et al December 5, 2012

Renal pelviceal keratinizing squamous metaplasia with sparing of pyramidal zones, "Beyond the Abstract," by Richard H. Siderits, MD and Noah S. Rolleri, MS-IV November 26, 2012

Papillary renal cell carcinoma is associated with PTEN hamartoma tumor syndrome, "Beyond the Abstract," by Steven C. Campbell, MD, PhD, et al. November 14, 2012

Preoperative metastatic status, level of thrombus and body mass index predict overall survival in patients undergoing nephrectomy and inferior vena cava thrombectomy, "Beyond the Abstract," by Philippe E. Spiess, MD, MSc, FACS, FRCS(C) October 26, 2012

Page 9 of 11